Table 5. Details of EOAI and mean transvalvular gradients within the identified SVD patients within and outside the study period.
| ID | Age, years | Sex | Year of implant | Year of reintervention | Durability months | Valve type | Valve size, mm | BSA, m2 | EOAI | Postop mean gradient, mmHg | Reintervention mean gradient | Pathology |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 65 | F | 2016 | 2019 | 31 | Trifecta | 23 | 1.78 | 1.01 | 4 | 5 | AR |
| 2 | 89 | F | 2017 | 2019 | 17 | Trifecta GT | 21 | 1.52 | 1.09 | 5 | 5 | AR |
| 3 | 80 | M | 2017 | 2020 | 20 | Trifecta | 25 | 2.10 | 0.96 | 8 | 17 | AR |
| Cases prior to January 2015 and SVD at >3 years | ||||||||||||
| 4 | 75 | M | 2014 | 2018 | 39 | Trifecta | 23 | 1.97 | 0.91 | 11 | 15 | AR |
| 5 | 75 | M | 2012 | 2018 | 72 | Trifecta | 23 | 2.16 | 0.86 | 13 | 16 | AR |
| 6 | 70 | F | 2013 | 2019 | 67 | Trifecta | 25 | 1.83 | 1.12 | 12 | 83 | Mixed AR/AS |
| 7 | 82 | M | 2013 | 2019 | 66 | Trifecta | 25 | 2.08 | 0.96 | 15 | 22 | AR |
AR: aortic regurgitation; AS: aortic stenosis; BSA: body surface area; EOAI: indexed effective orifice area; F: female; GT: Glide Technology; M: male; SVD: structural valve deterioration